Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cadrenal Therapeutics, Inc. issued 37,143 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for exercise price of $5.625 per share.
- Security
- warrant
- Shares
- 37,143 shares of Common Stock
- Purchaser
- H.C. Wainwright & Co., LLC
- Consideration
- exercise price of $5.625 per share
Exact text from the filing
Shares. The Placement Agent Warrants will have substantially the same terms as the Series B-1 Warrants, except that the Placement Agent Warrants will have an exercise price of $5.625 per share, which is equal to 125% of the exercise price of the New Warrants. 1 Terms of the New Warrants The New Warrants will be immediately exercisable at an exercise price of
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cadrenal Therapeutics, Inc. issued 571,430 shares of Common Stock of warrant to Holder of Existing Warrants for exercise price of $4.50 per share.
- Security
- warrant
- Shares
- 571,430 shares of Common Stock
- Purchaser
- Holder of Existing Warrants
- Consideration
- exercise price of $4.50 per share
Exact text from the filing
of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase up to an aggregate of 571,430 shares of Common Stock, at the adjusted exercise price of $4.50 per share (reduced from the initial exercise price of $16.50 per share). The offer and resale of the shares of Common Stock underlying the Existing Warrants (the “Existing Warrant
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Inducement Agreement with a holder of Existing Warrants valued at approximately $2.5 million (effective 2026-03-31).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- a holder of Existing Warrants
- Value
- approximately $2.5 million
- Effective
- 2026-03-31
Exact text from the filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
View on SEC.gov